Protagenic Therapeutics Announces Termination of CFO Alexander Arrow
On March 31, 2026, Protagenic Therapeutics, Inc. announced that its Board of Directors notified Alexander Arrow, MD, the Companyβs Chief Financial Officer, that his employment will be terminated. The termination is scheduled to be effective as of April 30, 2026. The filing, dated April 6, 2026, was signed by Executive Chairman Garo H. Armen. No successor for the CFO role was named in this specific filing, and no further details regarding the reason for the departure or transition plans were provided. Protagenic Therapeutics is a biotechnology company focused on developing neuroactive peptides for the treatment of stress-related disorders. The company's common stock and warrants are currently traded on the OTC Markets under the symbols PTIX and PTIXW, respectively.